General Information of Drug (ID: DMOPUIH)

Drug Name
PMID15546730C2 Drug Info
Synonyms UNII-N9PH4O199D; N9PH4O199D; GTPL8136; BDBM13268
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11153014
CAS Number
CAS 302961-18-8
TTD Drug ID
DMOPUIH

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [3]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [5]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [6]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [6]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [7]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [6]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [8]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [3]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
Ro-4396686 DM5DMCH Discovery agent N.A. Investigative [11]
CEP-5104 DMV43GY Discovery agent N.A. Investigative [12]
CEP-6331 DMNXBTD Discovery agent N.A. Investigative [12]
JNJ-10198409 DM9GDP5 Discovery agent N.A. Investigative [13]
1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane DMD7WNV Discovery agent N.A. Investigative [14]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Janus kinase 3 (JAK-3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tofacitinib DMBS370 Rheumatoid arthritis FA20 Approved [15]
Ritlecitinib DMYKNME Alopecia areata ED70.2 Approved [16]
ASP-015K DMZ1UOI Psoriasis vulgaris EA90 Phase 3 [17]
VX-509 DM2U3MX Rheumatoid arthritis FA20 Phase 2/3 [18]
Cerdulatinib DMSCR2H B-cell lymphoma 2A86 Phase 2 [16]
ATI-501 DMTY6OF Alopecia ED70 Phase 2 [19]
ATI-502 DM8NODR Alopecia ED70 Phase 2 [20]
TD-8236 DMTOMJN Asthma CA23 Phase 2 [21]
ALXN2075 DM1BSD8 Non-hodgkin lymphoma 2B33.5 Phase 1/2 [22]
SNA-125 DM8L1GJ Atopic dermatitis EA80 Phase 1 [16]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BK3 DM6YQO3 N. A. N. A. Patented [23]
Doramapimod DM6BU7N Inflammatory bowel disease DD72 Patented [24]
3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine DM0DYAU N. A. N. A. Patented [23]
Unii-I92MU0V408 DMUD7H8 N. A. N. A. Patented [24]
US8933228, 3 DMPNCOL N. A. N. A. Patented [24]
SB19065 DM2MQD0 N. A. N. A. Patented [25]
US9108950, 1 DMPT2ZS N. A. N. A. Patented [26]
US8933228, Ref 2 DMKEX51 N. A. N. A. Patented [27]
BK7 DMQD4X2 N. A. N. A. Patented [23]
PP121 DMU8KTO Discovery agent N.A. Investigative [28]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID24900538C2c DM5PATM Discovery agent N.A. Investigative [29]
Drug(s) Targeting B lymphocyte kinase (BLK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ N. A. N. A. Patented [30]
PMID24915291C38 DMBXT9J Discovery agent N.A. Investigative [31]
PMID24915291C31 DMN7QB8 Discovery agent N.A. Investigative [31]
Drug(s) Targeting Proto-oncogene c-Src (SRC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [3]
Bosutinib DMTI8YE Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [3]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [32]
Herbimycin A DM6YWBF Solid tumour/cancer 2A00-2F9Z Approved [33]
AL3818 DM3WP0N Alveolar soft part sarcoma 2A60-2C35 Phase 3 [34]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [34]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [35]
KX-01 DMF0NA9 Actinic keratosis EK90.0 Phase 3 [16]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [36]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [37]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B lymphocyte kinase (BLK) TTNDSC3 BLK_HUMAN Inhibitor [2]
Fyn tyrosine protein kinase (FYN) TT2B9KF FYN_HUMAN Inhibitor [2]
Hematopoietic cell kinase (HCK) TT42OGM HCK_HUMAN Inhibitor [2]
Janus kinase 3 (JAK-3) TTT7PJU JAK3_HUMAN Inhibitor [2]
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [2]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [2]
Tyrosine-protein kinase Fgr (FGR) TTPOGS1 FGR_HUMAN Inhibitor [2]

References

1 Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck). Bioorg Med Chem Lett. 2003 Nov 17;13(22):4007-10.
2 Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6.
3 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
4 National Cancer Institute Drug Dictionary (drug id 596693).
5 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
6 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
7 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
8 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
10 National Cancer Institute Drug Dictionary (drug id 596693).
11 Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
12 Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9.
13 (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
14 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
18 Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
19 Clinical pipeline report, company report or official report of Aclaris Therapeutics.
20 ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
21 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
22 The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
23 Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037.
24 Respiratory formulations and compounds for use therein. US8933228.
25 Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same. US9062066.
26 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. US9108950.
27 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors. US9724347.
28 Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
29 Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9.
30 Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
31 Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
32 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
33 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
34 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
35 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
36 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
37 Clinical pipeline report, company report or official report of Turning Point Therapeutics.